(Q37130104)

18 August 2017

1 reference

title

Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review (English)

1 reference

18 August 2017

0 references

1 reference

M F B Silva

1

1 reference

18 August 2017

C C P Aires

2

1 reference

18 August 2017

P B M Luis

3

1 reference

18 August 2017

J P N Ruiter

4

1 reference

18 August 2017

L IJlst

5

1 reference

18 August 2017

M Duran

6

1 reference

18 August 2017

R J A Wanders

7

1 reference

18 August 2017

I Tavares de Almeida

8

1 reference

18 August 2017

publication date

4 April 2008

1 reference

Journal of Inherited Metabolic Disease

18 August 2017

published in

1 reference

18 August 2017

volume

31

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

205-216

1 reference

Effect of L-carnitine treatment for valproate-induced hepatotoxicity

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0841-X

Valproic acid hepatic fatalities. III. U.S. experience since 1986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0841-X

Valproic acid hepatic fatalities. II. US experience since 1984.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0841-X

The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0841-X

Urinary metabolites of valproic acid in epileptic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0841-X

Chronic valproate administration reduces fasting ketonemia in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0841-X

Pharmacokinetics, drug interactions, and tolerability of valproate.

21 January 2018

1 reference

12 December 2020

Valproate-induced hepatic injury: analyses of 23 fatal cases

1 reference

12 December 2020

Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity

1 reference

12 December 2020

Complete beta-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase

1 reference

12 December 2020

Fatal liver failure in 16 children with valproate therapy

1 reference

12 December 2020

Influence of valproic acid on the expression of various acyl-CoA dehydrogenases in rats

1 reference

12 December 2020

l-Carnitine Supplementation in Childhood Epilepsy: Current Perspectives

1 reference

12 December 2020

Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience

1 reference

12 December 2020

Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?

1 reference

12 December 2020

Neurological deterioration in patients with urea cycle disorders under valproate therapy--a cause for concern

1 reference

12 December 2020

Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide

1 reference

12 December 2020

Valproate-induced hyperammonemic encephalopathy

1 reference

12 December 2020

Gene expression profiles of murine fatty liver induced by the administration of valproic acid

1 reference

12 December 2020

Pharmacodynamic properties of N-dipropylacetic acid

1 reference

12 December 2020

Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid

1 reference

12 December 2020

The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism

1 reference

12 December 2020

Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI-MS/MS.

1 reference

12 December 2020

In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions.

1 reference

12 December 2020

Mechanisms of drug-induced liver injury.

1 reference

12 December 2020

Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy

1 reference

12 December 2020

Valproic acid for the treatment of myeloid malignancies

1 reference

12 December 2020

Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers.

1 reference

12 December 2020

Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency

1 reference

12 December 2020

On the rate-determining step of fatty acid oxidation in heart. Inhibition of fatty acid oxidation by 4-pentenoic acid

1 reference

12 December 2020

Evidence of inherited urea cycle defect in a case of fatal valproate toxicity

1 reference

12 December 2020

Studies on the extra-mitochondrial CoA-ester formation of valproic and Δ4-valproic acids

1 reference

12 December 2020

Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites.

1 reference

12 December 2020

The relationship between mitochondrial activation and toxicity of some substituted carboxylic acids

1 reference

12 December 2020

Interaction between anticonvulsants and human placental carnitine transporter

1 reference

12 December 2020

Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals

1 reference

12 December 2020

Progressive infantile neurodegeneration caused by 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency: a novel inborn error of branched-chain fatty acid and isoleucine metabolism

1 reference

12 December 2020

The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats

1 reference

12 December 2020

Identification of Metabolites of Valproic Acid in Serum of Humans, Dog, Rat, and Mouse

1 reference

12 December 2020

Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid

1 reference

12 December 2020

Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria

1 reference

12 December 2020

Studies on the reactivity of acyl glucuronides--III. Glucuronide-derived adducts of valproic acid and plasma protein and anti-adduct antibodies in humans

1 reference

12 December 2020

Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid

1 reference

12 December 2020

Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid

1 reference

12 December 2020

Mitochondrial metabolism of valproic acid

1 reference

12 December 2020

Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans

1 reference

12 December 2020

Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency

1 reference

12 December 2020

Influence of valproic acid on hepatic carbohydrate and lipid metabolism

1 reference

12 December 2020

Valproic Acid and Metabolites: Pharmacological and Toxicological Studies

1 reference

12 December 2020

Hepatotoxicity due to mitochondrial dysfunction

1 reference

12 December 2020

Epidemiology, classification, natural history, and genetics of epilepsy

1 reference

12 December 2020

Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.

1 reference

12 December 2020

Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid

1 reference

12 December 2020

Studies on the metabolic fate of valproic acid in the rat using stable isotope techniques

1 reference

12 December 2020

The occurrence of C6--C10-dicarboxylic acids in urine from patients and rats treated with dipropylacetate

1 reference

12 December 2020

Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2.

1 reference

12 December 2020

Divalproex-ER pharmacokinetics in older children and adolescents

1 reference

12 December 2020

Binding of a valproate metabolite to the trifunctional protein of fatty acid oxidation

1 reference

12 December 2020

Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates

1 reference

12 December 2020

Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?

1 reference

12 December 2020

Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency

1 reference

12 December 2020

Relationship between unusual hepatic acyl coenzyme A profiles and the pathogenesis of Reye syndrome.

1 reference

12 December 2020

Reversal of valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts

1 reference

12 December 2020

The role of carnitine supplementation during valproic acid therapy

1 reference

12 December 2020

Pharmacology of valproate

1 reference

12 December 2020

Late onset lipid storage myopathy due to multiple acyl CoA dehydrogenase deficiency triggered by valproate

1 reference

12 December 2020

Reye-like syndrome associated with valproic acid therapy

1 reference

12 December 2020

Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities.

1 reference

12 December 2020

Stereochemical studies on the beta-oxidation of valproic acid in isolated rat hepatocytes

1 reference

12 December 2020

Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy.

1 reference

12 December 2020

The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies

1 reference

12 December 2020

Carnitine as an antidote for acute valproate toxicity in children

1 reference

12 December 2020

Human brain, plasma, and cerebrospinal fluid concentration of sodium valproate after 72 hours of therapy

1 reference

12 December 2020

Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance

1 reference

12 December 2020

Pharmacokinetics of L-carnitine

1 reference

12 December 2020

Inappropriate liver transplantation in a child with Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced acute liver failure

1 reference

12 December 2020

Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy

1 reference

12 December 2020

Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry

1 reference

12 December 2020

Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes

1 reference

12 December 2020

Clinical pharmacokinetics of valproic acid--1988.

1 reference

12 December 2020

Drug-induced liver injury: summary of a single topic clinical research conference

1 reference

12 December 2020

Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency

1 reference

12 December 2020

Valproic acid toxicity: overview and management

1 reference

12 December 2020

Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse

1 reference

12 December 2020

Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions

1 reference

12 December 2020

Clinical pharmacokinetics of valproic acid

1 reference

12 December 2020

Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adults

1 reference

12 December 2020

Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure

1 reference

12 December 2020

Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma

1 reference

12 December 2020

Hepatic hydrolysis of octanoyl-CoA and valproyl-CoA in control and valproate-fed animals

1 reference

12 December 2020

Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines

1 reference

12 December 2020

Metabolism of branched medium chain length fatty acid. II--beta-oxidation of sodium dipropylacetate in rats

1 reference

12 December 2020

Effect of metabolites of valproic acid on the metabolism of GABA in brain and brain nerve endings.

1 reference

12 December 2020

Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS

1 reference

12 December 2020

Studies on the beta-oxidation of valproic acid in rat liver mitochondrial preparations

1 reference

12 December 2020

Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats

1 reference

12 December 2020

Inhibition of carnitine biosynthesis by valproic acid in rats--the biochemical mechanism of inhibition

1 reference

12 December 2020

Valproic acid and the liver.

1 reference

12 December 2020

Differential effect of valproate and its Delta2- and Delta4-unsaturated metabolites, on the beta-oxidation rate of long-chain and medium-chain fatty acids.

1 reference

12 December 2020

10.1007/S10545-008-0841-X

Identifiers

DOI

1 reference

18 August 2017

1 reference